Epigenome and Epigenetic Analysis
The epigenome is a multitude of chemical compounds that tells the genome what to do. The complete assembly of human genome is about 3 billion base pairs of DNA that makes each of the individual unique. DNA holds the instructions for building the proteins that carry out different functions in a cell. The epigenome is made up of chemical compounds and proteins that can attach to DNA and direct such actions as turning genes on or off, controlling the production of proteins in particular cells.
- Bioinformatics Approach
- Biostatistics Approach.
- Next Generation Sequenceing Techniques
- Different Assays Techniques.
- Genome based analaysis
Related Conference of Epigenome and Epigenetic Analysis
November 17-18, 2025
18th International Conference on Human Genomics and Genomic Medicine
Paris, France
March 09-10, 2026
21th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
Singapore City, Singapore
June 18-19, 2026
16th International Conference on Human Genetics and Genetic Diseases
Singapore City, Singapore
June 18-19, 2026
19th International Conference on Genomics & Pharmacogenomics
Singapore City, Singapore
Epigenome and Epigenetic Analysis Conference Speakers
Recommended Sessions
- Cell Therapy
- Anti-Aging and Regenerative Medicine
- Biobanking
- Biological Tissue Substitutes
- Biomaterials and Bioengineering
- Bone and Cartilage Tissue Engineering
- Cancer Cell Biology
- Cell & Organ Regeneration
- Cell Engineering
- Dental Stem Cells and Tooth Regeneration
- Epigenome and Epigenetic Analysis
- Future of Cancer Care
- Gene Therapy
- Immunology
- Novel Approaches in Guided Tissue Regeneration
- Organ Engineering
- Personalized Medicine
- Stem cells
- Tissue Culture & Preservation
- Tissue Engineering
- Tissue Repair And Regeneration
- Translational Medicine
- Vitrification
Related Journals
Are you interested in
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (France)
- Bioinformatics - HUMAN GENOME 2025 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (France)
- Cancer Genomics - HUMAN GENOME 2025 (France)
- Cancer Stem Cells and Oncology - Stemgen 2026 (France)
- Cardiovascular Regeneration - Stemgen 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (France)
- Cognitive Computing - HUMAN GENOME 2025 (France)
- Computational Biology - HUMAN GENOME 2025 (France)
- Drug Detection & Development in Bioinformatics - HUMAN GENOME 2025 (France)
- Emergency Medicine - HUMAN GENOME 2025 (France)
- Epigenetics Biomarkers - HUMAN GENOME 2025 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (France)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (France)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (France)
- Genetically Modified Organisms - HUMAN GENOME 2025 (France)
- Genome Mapping - HUMAN GENOME 2025 (France)
- Genomic Approach to Drug Discovery - HUMAN GENOME 2025 (France)
- Genomic Information in Medicine - HUMAN GENOME 2025 (France)
- Genomic Vaccination - HUMAN GENOME 2025 (France)
- Genomics - HUMAN GENOME 2025 (France)
- Human Gene Therapy - HUMAN GENOME 2025 (France)
- Human Genetics - HUMAN GENOME 2025 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (France)
- Infectious Diseases - HUMAN GENOME 2025 (France)
- Medicine Genomics - HUMAN GENOME 2025 (France)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (France)
- Personalized Medicine - HUMAN GENOME 2025 (France)
- Pharma Genomics & Pharma Informatics - HUMAN GENOME 2025 (France)
- Preimplantation Genetic Diagnosis - HUMAN GENOME 2025 (France)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (France)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (France)